|
Pretargeted
adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients:
a pilot study
Grana C, Chinol M, Robertson C, Mazzetta C, Bartolomei M, De Cicco C,
Fiorenza M, Gatti M, Caliceti P, Paganelli G
Division of Nuclear Medicine,
European Institute of Oncology, via Ripamonti 435, I-20141, Milano, Italy
In a previous study we applied a three-step avidin-biotin pretargeting approach
to target 90Y-biotin to the tumour in patients with recurrent high grade glioma.
The
encouraging results obtained in this phase I-II study prompted us to apply the
same approach in an adjuvant setting, to evaluate
(i) time
to relapse and
(ii) overall survival.
We
enrolled 37 high grade glioma patients, 17 with grade III glioma and 20 with
glioblastoma, in a controlled open non-randomized study.
All
patients received surgery and radiotherapy and were disease-free by
neuroradiological examinations.
Nineteen
patients (treated) received adjuvant treatment with radioimmunotherapy.
In the
treated glioblastoma patients, median disease-free interval was 28 months
(range=9-59); median survival was 33.5 months and one patient is still without
evidence of disease.
All 12 control glioblastoma patients died after a median
survival from diagnosis of 8 months.
In the
treated grade III glioma patients median disease-free interval was 56 months
(range=15-60) and survival cannot be calculated as only two, within this group,
died.
Three-step
radioimmunotherapy promises to have an important role as adjuvant treatment in
high grade gliomas, particularly in glioblastoma where it impedes progression,
prolonging time to relapse and overall survival.
A
further randomized trial is justified.
Copyright
2002 The Cancer Research Campaign.
PMID: 11870507 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11870507&dopt=Abstract |
